PSY17 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO
May 1, 2008, 00:00
10.1016/S1098-3015(10)70498-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)70498-8/fulltext
Title :
PSY17 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70498-8&doi=10.1016/S1098-3015(10)70498-8
First page :
Section Title :
Open access? :
No
Section Order :
217